10% of patients diagnosed with Parkinson's disease are between the ages of 21 and 50. For those with young-onset Parkinson's disease, researchers report the foundations for the disease may have been apparent before they were born. The study also points to a drug, currently approved to treat precancerous skin growths, that has the potential to reduce elevated levels of alpha-synuclein.
